Morgan Ebert, Managing Editor

AAP updates guidance on recognizing and managing iatrogenic opioid dependence and withdrawal in children prescribed opioids.

Survey finds 30% of children missing school due to anxiety miss over a week; experts urge early intervention and therapy to address school avoidance.

Higher maternal vitamin D in early pregnancy linked to better fluid and overall cognition in children, especially among those of Black mothers.

FDA approves first generic iron sucrose injection for treating iron deficiency anemia in CKD patients 2 years and older.

FDA accepts priority review of gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urogenital gonorrhea in patients ≥12 years.

Pharmacotherapy use for pediatric obesity rose after AAP’s 2023 guidelines, though overall rates remain low compared to nutrition counseling.

A US study finds influenza-associated necrotizing encephalopathy in children has high mortality and disability, underscoring need for early care.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from July 2025.

Take a quick look at everything you may have missed last month, including the top FDA approvals and latest clinical updates.

The FDA approved concizumab-mtci (Alhemo; Novo Nordisk) for hemophilia A/B without inhibitors, offering once-daily subcutaneous prophylaxis that significantly reduces bleeding rates.

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

Many families face common potty training challenges, including anxiety and setbacks, highlighting the need for patience and personalized strategies.

The FDA has approved avatrombopag and new sprinkle formulation for children ≥1 year with chronic ITP, offering an oral, food-flexible treatment option.

Most youth with type 1 diabetes in sub-Saharan Africa lack autoimmune markers, suggesting a distinct, non-autoimmune form of insulin-deficient diabetes.

Nirsevimab reduced RSV-related illness by up to 98% and lowered the amount of hospitalizations and health care use among healthy term infants in a real-world study.

A new polygenic risk score enhances obesity risk prediction from childhood to adulthood, offering new insights for early intervention and prevention strategies.

U.S. public schools enhance student mental health support through screenings, yet face challenges in ensuring effective follow-up care and resources.

Childhood cardiovascular health is crucial for lifelong benefits, enhancing cognitive, metabolic, and mental well-being while reducing disease risks.

Early antibiotic exposure disrupts infant immune development by altering gut microbiota, highlighting inosine's potential as a therapeutic target for immune restoration.

A recent study reveals a staggering 763% rise in nicotine pouch ingestions among young children, highlighting urgent public health concerns.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The FDA approves gardenia (genipin) blue as a natural food color, enhancing options for manufacturers and supporting the shift away from synthetic dyes.

A study reveals declining US neonatal mortality overall, yet highlights rising deaths from fetal malnutrition, emphasizing ongoing disparities in neonatal health outcomes.

Wearable-derived biorhythms predicted postoperative complications in children up to 3 days early, offering a new tool for remote pediatric monitoring.

A clinical trial found CBD was safe and well-tolerated in autistic boys, with some showing behavioral improvements, though placebo effects were strong.

Even low-level lead exposure in early childhood may speed up memory loss, according to a new study using a cognitive task to measure forgetting rates.

A proinflammatory maternal diet during pregnancy was linked to a 16% higher risk of type 1 diabetes in offspring, a Danish cohort study finds.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

A roundup of the most impactful FDA approvals in pediatric health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

A look back at the most important FDA approvals, clinical research, and expert perspectives shaping pediatric health care in the first half of 2025.